Craft
  • Home
  •  / Vertex Pharmaceuticals
Vertex Pharmaceuticals

Vertex Pharmaceuticals

Products

6

FY, 2020

Revenue

$7.6 B

FY, 2021

Market Capitalization

$72.5 B

2022-09-19

Vertex Pharmaceuticals Summary

Company summary

Overview
Vertex Pharmaceuticals is a biotechnology company that invests in scientific innovation to create medicines for people with cystic fibrosis. It markets TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its pipeline includes a pipeline for Alpha-1 antitrypsin deficiency; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency; and VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and other serious kidney diseases.
Type
Public
Founded
1989
HQ
Boston, MA, US | view all locations
Website
https://www.vrtx.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Reshma Kewalramani

    Reshma Kewalramani, Chief Executive Officer, President & Director

  • David Altshuler

    David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer

  • Carmen Bozic

    Carmen Bozic, Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer

  • Stuart A. Arbuckle

    Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer

    Operating MetricsView all

    Products

    6
    20.0%

    FY, 2020

    LocationsView all

    30 locations detected

    • Boston, MA HQ

      United States

      50 Northern Ave

    • Providence, RI

      United States

      225A Carolina Avenue

    • San Diego, CA

      United States

      3215 Merryfield Row

    • Washington, DC

      United States

      1050 K St NW

    • Watertown, MA

      United States

      490 Arsenal Way #110

    • St Leonards, NSW

      Australia

      level 3 suite 3/601 Pacific Hwy

    and 24 others

    Vertex Pharmaceuticals Financials

    Summary financials

    Revenue (Q2, 2022)
    $2.2B
    Cash (Q2, 2022)
    $8.7B
    Enterprise value
    $64.3B

    Footer menu